Using PCa mouse models with PTEN mutations followed by RB1 loss, Ku et al. [26] showed that PTEN and RB1 serve as lineage plasticity markers that enhance tumor metastasis, while the additional loss of tumor suppressor TP53 allows tumors to resist antiandrogen therapy. The gene discussed is PTEN; the disease is posterior cortical atrophy.